Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Q2 2021 Earnings Presentation
13 slides from Genedx's earnings presentation, 2021
Slide 1: Second Quarter Earnings Presentation
Second Quarter Earnings Presentation 1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for
Slide 3: Corporate Snapshot
Corporate Snapshot ~1,000 Employees 2020 revenue 12 million Generating and Accessioning 160+ PhD’s Of $179mn de-identified managing 35+ > 200,0001 ($148mn clinical records, petabytes of data Next Generation excluding per month many with Sequencing tests COVID-19) genomic data annually 1 Annualized R
Slide 4: Business Highlights
Business Highlights 2Q211 YoY Revenue growth of 56% 2Q YoY increase of 85% in diagnostics tests resulted2 Expanded health system collaborations, adding NorthShore University HealthSystem, AdventHealth, and Avera Health Further strengthened C-suite bench, adding a Chief Financial Officer, Chief Data
Slide 5: Second Quarter GAAP Financial Highlights
Second Quarter GAAP Financial Highlights 2Q 20211 – Financial Highlights 2Q 2021 – Segment Mix USD Millions USDM 2Q 2020 2Q 2021 4% 8% Total Revenue $30.1 $46.9 Diagnostic Test GAAP Net Loss ($32.1) ($45.4) COVID-19 Gross Profit ($5.9) ($2.8) Other 88% Gross Margin (20%) (6%) 1 3 months ended 6/30/2
Slide 6: Second Quarter Non-GAAP Financial Highlights
Second Quarter Non-GAAP Financial Highlights 2Q 20211 – Financial Highlights 2Q 2021 – Segment Mix USD Millions USDM 2Q 2020 2Q 2021 4% Total Adjusted 8% ($28.5) ($36.4) EBITDA2 Diagnostic Test Adjusted Gross ($2.8) ($3.1) Profit3 COVID-19 Adjusted Gross (9%) (7%) Margin4 88% Other 1 3 months ended
Slide 7: Resulted Volumes
Resulted Volumes1 Cumulative Resulted Volumes (excluding COVID-19) Since January 1, 2020 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 1 Represents resulted volume excluding COVID-19 7
Slide 8: Financial Snapshot
Financial Snapshot ($ in millions) P&L 2018 2019 2020 YTD 2021 Revenue $133 $196 $179 $111 Gross Margin 31% 39% -3% -9% Adjusted Gross Margin 35% 40% 17% 8% Net Loss (24) (30) (241) (236) 1 Adjusted EBITDA (18) (19) (107) (60) Balance Sheet 2019 2020 1Q21 2Q21 (2) Cash & Equivalents $115 $108 $59 $5
Slide 9: Appendix
Appendix 9
Slide 10: Non-GAAP Gross Margin Reconciliation
Non-GAAP Gross Margin Reconciliation 2Q 2021 – non-GAAP Gross Margin Reconciliation USD Millions 10
Slide 11: Non-GAAP Gross Margin Reconciliation
Non-GAAP Gross Margin Reconciliation YTD 2021 – non-GAAP Gross Margin Reconciliation USD Millions 11
Slide 12: Non-GAAP Adjusted EBITDA Reconciliation
Non-GAAP Adjusted EBITDA Reconciliation 2Q 2021 – non-GAAP Adjusted EBITDA Reconciliation USD Millions 12
Slide 13: Non-GAAP Adjusted EBITDA Reconciliation
Non-GAAP Adjusted EBITDA Reconciliation YTD 2021 – non-GAAP Adjusted EBITDA Reconciliation USD Millions 13